The role of w3 PUFFA in Patients with Metabolic Syndrome and Endothelial Dysfunction

• DOI: 10.20944/preprints202305.1570.v1
• Publication Date: 2023-05-24T02:10:51Z
• Authors: Monika Jankajova; Dominik Pella; Pavol Zenuch; Zuzana Zenuchova; Stefan Toth; Peter Kalanin; Jan Fedacko
• Keywords: Reactive hyperemia; Endothelial Dysfunction

Aim: Evaluation of role supplementation omega-3 polyunsaturated fatty acids on endothelial function in patients with metabolic syndrome. 
 Methods: Total 80 syndrome were enrolled to two groups. We evaluated subjects before and after three-month treatment dose 2.4g daily (800mg 3 times a day) vs placebo. Using the Endo-PAT2000 device (Itamar Medical Ltd. Caesarea, Israel), reactive hyperemia index – parameter augmentation index– arterial stiffness measured. Plasmatic level glutation peroxidase, homocysteine, apolipoprotein B lipoprotein (a) also evaluated.
 Results: The average values n-3PUFA was 1.62 ± 0.42 , whereas 1.96 0.62 at end study (p<0.005). Augmentation changed from 14.66 19.55 9.21 15.64 (p=0.003). observed statistically significant decrease apolipopotein (0.94 0.36 1.13 0.35, p = 0.001) homocysteine (19.31 5.29 vs. 13.78 3.05, increase glutathion perxidase plasma levels (41.65 8.90 45.20 8.01), p=0.001.
 Conclusion: have improvement treated daily.